big pharma is watching

Big and Specialty Pharma likes emerging biotechs

Imo, another reason to remain optimistic looking forward to our imminent US listing.

The huge exposure that will be afforded to a small aussie bio-spec who's CVac Phase IIb clinical trial is continually being compared to Dendreons Provenge vaccine will certainly attract the attention of some major players.

This fact probably not taken into consideration when Southern Cross Equity's Senior Biotech Analyst Stuart Roberts compiled the following report this week and set PRR 12 month target price at only 60c

"A growing trend in the global pharmaceutical industry in recent years has been for Big and Specialty Pharma companies to acquire emerging biotech companies as a way of battling declining pipelines, looming patent expirations, a slowdown in drug spending growth in major Western markets, and the rising costs of drug development."

click here for the full report